Here’s what you should know:
1. The company reported a 6 percent growth in year-over-year sales.
2. Boston Scientific posted net generally accepted accounting principle earnings of $146 million or $0.11 per share. In fiscal year 2016, Boston Scientific lost $207 million or -$0.15 per share.
3. Boston Scientific’s notable acquisitions included EndoChoice and Symetis SA during the second quarter.
4. Concerning rest-of-year outlooks, Boston Scientific expects net revenues between $8.89 billion to $8.99 billion, which is a slight increase from the beginning of year estimate of $8.8 billion to $8.9 billion.
More articles on gastroenterology:
Olympus to pay $6.6M in duodenoscope-related damages — 6 key takeaways
Boston Scientific continues to pour money into endoscopy — Why?
Staying relevant — Dr. Larry Kosinski on the future of GI in ASCs
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
